Appili Therapeutics (APLIF) announced that its President and CEO, Don Cilla, will join Aditxt (ADTX) Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4. The discussion will cover the Company’s recent operational highlights, including $117M in new federal funding applications, and the status of the going-private transaction with Aditxt. Cilla will join Aditxt to explore the escalating threat of emerging infectious diseases and highlight the vital role of strategic partnerships in developing innovative treatments and improving global public health. The Aditxt Weekly Update will also provide insights into Appili’s diverse near-to-market portfolio, designed to address critical unmet patient needs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLIF:
- Biotech Alert: Searches spiking for these stocks today
- Appili Therapeutics Seeks $117.5 Million in Federal Funding for Infectious Disease Treatments
- Appili Therapeutics announces submission of government funding proposals
- Appili Therapeutics expects Aditxt transaction to close in Q1
- Appili Therapeutics Advances Pipeline with Strong Shareholder and Government Support